Kyle Gash, PharmD

The chemotherapy-free regimen blinatumomab and ponatinib is associated with significantly improved PFS and OS compared to Hyper-CVAD with ponatinib, with less non-relapse morality and a reduced reliance on allo-SCT in Ph+ ALL. doi.org/10.1002/ajh.70… @AjHematology @UTMDAnderson

Adding blinatumomab and inotuzumab to hyperCVAD in younger B-cell #ALL improves EFS from 66% to 89% doi.org/10.1002/ajh.70… @AjHematology @UTMDAnderson

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study | Blood Cancer Journal share.google/vYKyXXGrKkA6Bm…

Axi-cel can now be used for R/R PCNSL! HT @samyamshon #lymsm #tcellrx

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML ashpublications.org/blood/article/… #AML #leusm

🩸 ASH Plenary Spotlight PARADIGM phase 2 trial compares azacitidine plus venetoclax (aza-ven) with intensive induction chemotherapy (IC) in fit, IC-eligible adults with newly diagnosed AML. Key findings (n=172): • Higher overall response with aza-ven vs IC (88 percent vs 62 percent; P<0.001) • Higher composite complete remission rate (81 percent vs 55 percent; P<0.001) • 1-year EFS 53 percent with aza-ven vs 39 percent with IC (HR 0.61; P=0.017) • 30- and 60-day mortality both 0 percent with aza-ven, vs 3.5 percent and 4.7 percent with IC • Better early QOL, symptom burden, and depression scores with aza-ven • Fewer ICU admissions (0 vs 9.8 percent; P=0.003) • Fewer inpatient days during index hospitalization and over 6 months Conclusion: Aza-ven met the primary endpoint, showing improved EFS, higher responses, better tolerability, and improved QOL compared with IC in younger, fit AML patients. OS continues to mature. #ASH25 #AML #HemeTwitter @ASH_hematology

BsAb in CNS-involved lymphoma: real 🌎 data (n=41) #ASH25 Median age 57; 37 SCNSL / 4 PCNSL • 41% isolated CNS, 60% CNS + systemic relapse Prior lines: median 3; 46.5% CAR-T, 24% ASCT 💊 Tx: median 3 cycles • Epco 73% (23% mono; 77% combos) • Glofi 27% (9% mono; 91% combos)

This is the one of the most incredible outcome difference I have seen in myeloma: Results of the randomized Majestec-3 trial in myeloma. @mvmateos HR 0.17 !! Late breaker at #ASH25 @ASH_hematology meetings-api.hematology.org/api/abstract/v…

🚨 New data on seizure prophylaxis in CAR-T! A new study evaluated whether levetiracetam (LVT) prevents ICANS in patients receiving anti-CD19 CAR-T for LBCL. Using a propensity-matched cohort of 254 patients, the findings were clear: 🧠 No reduction in ICANS with LVT prophylaxis • Any-grade ICANS: 32.3% vs 37.1% (ns) • Severe ICANS (G2–4): 15.1% vs 16.1% (ns) 🩸 BUT: LVT was linked to higher early hematotoxicity (ICAHT) • G2–4 ICAHT: 37.3% → 63.9% (P < .001) 📉 No differences in OS, PFS, or non-relapse mortality. 🔍 Takeaway: Routine LVT prophylaxis does not prevent ICANS and may increase toxicity. More work needed to define if/when it should be used. ashpublications.org/bloodadvances/… #CAR_T #ICANS #Lymphoma #HemOnc #Immunotherapy #CellTherapy

DLBCL treatment has gotten more complicated Back in my day it was RCHOP if relapse salvage and ASCT

🚨 Exciting news for our leukemia patients! Ziftomenib just received FDA approval for relapsed/refractory NPM1-mutated AML — #leusm @KuraOncology Brief overview of key data: 1/ Phase II trial (KOMET‑001) treated 92 adults with relapsed/refractory NPM1-m AML using once-daily Ziftomenib (600 mg) monotherapy. 2/ PE: rate of CR/CRh 3/ Results CR/CRh rate: 22%, ORR: 33% ; among responders, 61% achieved undetectable MRD 4/ Median DOR: 4.6 months (range 2.8-7.4 m) 5/ Median OS: 6.6 months (95% CI: 3.6-8.6) 6/ Activity was consistent across subgroups including those with prior venetoclax treatment or co-mutations. 7/ Safety profile: Grade ≥3 febrile neutropenia (26 %), anemia (20 %), thrombocytopenia (20 %). Differentiation syndrome occurred in ~25 % (15 % were grade 3; no grade 4/5) doi.org/10.1200/JCO-25…

Top 10 ASH abstracts @mtmdphd #ASH25 1.2422- Redefining function high-risk (FHR) MM s/p QUAD and ASCT Median 2PFS -3.3 mo -FHR12, 2.7 mo -FHR18, 3.3 mo - FHR24 5.8 mo - FHR36. @End_myeloma @SusanBal9 FHR is the common poor prognostic factor in predictors of early relapse after CART in two seperate ASH abstracts @szusmani and Doris Hansen [ID=93]

📊 My favorite #ASH2025 abstracts on #MultipleMyeloma and #Amyloidosis. Do not mention lots of trials and heavy on amyloid. @mtmdphd

HISTORIC AND PARADIGM CHANGING: FDA approves daratumumab for high risk smoldering multiple myeloma based on the AQUILA trial— the FIRST ever treatment approved for this indication. Excellent news and thanks to @JNJInnovMed and the huge worldwide team of investigators for making it happen. @thanosdimop @SagarLonialMD @PlasmaCellPete

🚨The Future of BiTEs, especially in combination therapy trials, should be focused on fixed duration 👍 👍👍 🧵 Teclistamab Dosing Strategies in #MultipleMyeloma: Continuous vs. Fixed-Duration Therapy : 1/Study Snapshot 📊 Multicenter, real-world retrospective analysis (n=88) 💊 Compared continuous (n=72) vs. fixed-duration (n=16) teclistamab in relapsed/refractory #MM 🎯 Goal: Evaluate if stopping after deep response compromises outcomes #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما @oncodaily @MedwatchKate @MDPIOpenAccess @CancerNetwrk @KUcancercenter @SaudiMyeloma #السعودية

Dara-Tec in NTE-NDMM. I think we are still to see a patient being reported that receives BCMA-TCE in NDMM and does not become MRD negative. It makes us question everything else we are doing... meetings-api.hematology.org/api/abstract/v…

Censoring! Informed censoring in KM curves occurs when censoring is related to prognosis, sicker patients drop out early, biasing survival ⬆️. Unlike random censoring, it violates assumptions & distorts the curve. Look at numbers below curve to see how many people are censored

@DrRishabhOnco Impressive data from POLARGO 💥 Adding polatuzumab vedotin to R-GemOx nearly doubled PFS (7.4 vs 2.7 months) and cut the risk of death by 40% in transplant-ineligible R/R DLBCL. A strong case for moving Pola-based regimens earlier in the treatment paradigm. #Hematology #EHA2025

🧬 Not all DLBCLs are created equal - POLA knows the difference. 📊 Real-world (n = 740, 2015–24) Polatuzumab used in 🔹Frontline (305) 🔹R/R (435) COO classified by Hans IHC algorithm 🔥 R/R LBCL: •ORR 59.7% vs 36.3% ➜ OR 2.6 (p<0.0001) •CR 35.7% vs 17.7% ➜ OR 2.6 (p<0.0001) •PFS benefit → HR 0.64 (p = 0.0006) 💊 Frontline (Pola-R-CHP): No subtype gap → Pola neutralizes COO risk 💡 Takeaway: Hans IHC still rules 🧪 🔹 Non-GCB = POLA favorite in R/R 🔹 Frontline Pola-R-CHP = great equalizer 📖 Scheffer-Cliff et al., Clin Cancer Res 2025 DOI: aacrjournals.org/clincancerres/… #DLBCL #Lymphoma #HemOnc #OncoTwitter #ESMOOpen @OncoAlert @esmo_open @ASCO

Revumenib is now @US_FDA ✅ for R/R AML w/ NPM1 mutation (approved for KMT2A translocation previously). - ORR 46.9% - Response seen in all subgroups (comutations, previous HSCT, or high number of prior lines of Rx). #HemeTwitter @beatalleukemia @LeukDocJZ 👏👏